Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II

• Type: Another Publication in an International Scientific Journal
• Date: 2019

Authors

Vieira, R (Author) Other; Souto, SB (Author) Other; Sanchez Lopez, E (Author) Other; Machado, AL (Author) Other; Severino, P (Author) Other; Jose, S (Author) Other; Santini, A (Author) Other; Silva, AM (Author) Other; Fortuna, A (Author) Other; Garcia, ML (Author) Other; Souto, EB (Author) Other

Journal

Title: Journal of Clinical Medicine

Vol. 12 No. Article 2338

Final page: 1332

ISSN: 2077-0383

Publisher: MDPI

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 50 Citations

Scientific classification

CORDIS: Health sciences

Other information

Authenticus ID: P-00R-5TY

DOI: 10.3390/jcm8091332

Abstract (EN): Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic beta-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 20